Longeveron® Announces Key Leadership Updates
1. Than Powell appointed as interim CEO of Longeveron. 2. Dr. Joshua Hare becomes Executive Chairman of the Board. 3. Longeveron’s laromestrocel shows promise in pivotal clinical trials. 4. Clinical trials for laromestrocel targeting HLHS are fully enrolled. 5. A national search for a permanent CEO is underway.